- Home
- WRBY vs RARE Comparison
WRBY vs RARE Comparison
Compare WRBY & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRBY
- RARE
- Stock Information
- Founded
- WRBY 2010
- RARE 2010
- Country
- WRBY United States
- RARE United States
- Employees
- WRBY N/A
- RARE N/A
- Industry
- WRBY Ophthalmic Goods
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- WRBY Health Care
- RARE Health Care
- Exchange
- WRBY Nasdaq
- RARE Nasdaq
- Market Cap
- WRBY 2.7B
- RARE 2.6B
- IPO Year
- WRBY 2021
- RARE 2014
- Fundamental
- Price
- WRBY $26.75
- RARE $30.31
- Analyst Decision
- WRBY Buy
- RARE Strong Buy
- Analyst Count
- WRBY 16
- RARE 14
- Target Price
- WRBY $24.40
- RARE $86.64
- AVG Volume (30 Days)
- WRBY 1.4M
- RARE 1.4M
- Earning Date
- WRBY 11-06-2025
- RARE 11-04-2025
- Dividend Yield
- WRBY N/A
- RARE N/A
- EPS Growth
- WRBY N/A
- RARE N/A
- EPS
- WRBY N/A
- RARE N/A
- Revenue
- WRBY $821,347,000.00
- RARE $610,159,000.00
- Revenue This Year
- WRBY $17.17
- RARE $19.72
- Revenue Next Year
- WRBY $14.53
- RARE $23.29
- P/E Ratio
- WRBY N/A
- RARE N/A
- Revenue Growth
- WRBY 14.09
- RARE 26.77
- 52 Week Low
- WRBY $13.63
- RARE $25.81
- 52 Week High
- WRBY $29.73
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- WRBY 57.13
- RARE 49.05
- Support Level
- WRBY $26.63
- RARE $31.22
- Resistance Level
- WRBY $27.59
- RARE $31.80
- Average True Range (ATR)
- WRBY 0.68
- RARE 0.93
- MACD
- WRBY -0.01
- RARE 0.07
- Stochastic Oscillator
- WRBY 67.69
- RARE 35.88
About WRBY Warby Parker Inc.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.